Molecular Partners AG · SIX:MOLN
Molecular Partners — FuW Forum (Covid) (October 2020)
19 slides from Molecular Partners's conference presentation, Oct 28, 2020
Slide 1: Developing a Drug in and for a Global Pandemic
Developing a Drug in and for a Global Pandemic: Learnings from the Covid DARPin® Case on How to Overcome Barriers October 2020, Patrick Amstutz, CEO DARPin® is a registered trademark of Molecular Partners AG 1
Slide 2: Disclaimer
Disclaimer This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. T
Slide 3: Prophylactic / Therapeutic options for COVID
Prophylactic / Therapeutic options for COVID Repurposed Vaccines COVID Therapeutics Therapeutics Medical need Importance of inhibiting viral replication Size of population 3
Slide 4: From natural antibody response to a mixture
From natural antibody response to a mixture Vaccine/polyclonal antibodies Monoclonal antibody Monoclonal antibody mixture mutation mutation Controls the virus Virus may escape Controls the virus 4
Slide 5: Why an antibody mixture is likely not a global solution
Why an antibody mixture is likely not a global solution Antibody mixture Monoclonal antibodies drawbacks VS. ✗ High cost ✗ Amounts limited ✓ Effective ✗ Unstable ✗ Infused 5
Slide 6: One molecule to do the work of several
One molecule to do the work of several Antibody cocktail A single DARPin® with multi-specific binding 6
Slide 7: How it all began
How it all began: Imperative to act, initiative, teamwork & passion 7
Slide 8: What are DARPins?
What are DARPins? Custom-built therapies based on natural proteins with unique advantages High affinity and specificity Multi-specificity ighpotency High potencywith with ol wer lower riskrisk of an act Can acton onupup todistinct to 6 distinct of off target off-target effects effects targets at onc
Slide 9: Incredible speed to multi-specific DARPin Candidates
Incredible speed to multi-specific DARPin Candidates DARPin® library with 1012 modules > 400 anti-COVID > 100 tri-specific DARPin Design and identification of DARPin Modules Candidates MP0420 & MP0423 Week: 1 Week: 3 Week: 6 9
Slide 10: MP0420 & MP0423: Two COVID-DARPin candidates
MP0420 & MP0423: Two COVID-DARPin candidates Spike protein MP0420 MP0423 trimeric “open” conformation multi-RBD multi-mode HSA binder S1 - RBD domains RBD S1 - NTD domains binders NTD binder S2 domains 180° 50° S2 binder ▪ We are developing two distinct Covid-DARPin Candidates, MP0420 and MP0423 ▪ M
Slide 11: MP0420 & MP0423: DARPin solutions to SARS-Cov2
MP0420 & MP0423: DARPin® solutions to SARS-Cov2 MP0420 – best-in-class ➢ 3 different DARPins blocking the RBD (mAB mixture in one) for highest potency & to prevent viral escape ➢ Long half-life – single injection ➢ s.c. injection – simple application in ambulatory setting ➢ Low costs and high number
Slide 12: MP0420-DARPin Features and their Benefits
MP0420-DARPin Features and their Benefits Highest potent drug avoiding viral escape: Long-acting and safe drug candidate: Triple RBD – DARPin binder HSA DARPin Technology* • Cooperative binding for highest potency • Single injection carries out for months • Multi-specificity to prevent viral escape
Slide 13: Therapeutic effect, designed for global impact
Therapeutic effect, designed for global impact Subcutaneous injection High solubility and potency allows low volume injection DARPin: 0h, 6, 24h Simple high-yield manufacturing Highly validated bacterial fermentation simplifies production and scaling Placebo Long shelf-life and stability Can be stor
Slide 14: Collaborations essential during a global pandemic
Collaborations essential during a global pandemic ▪ A shared moral imperative to act rapidly as one cross-functional team ▪ Information flow in a true spirit of collaboration 14
Slide 15: Why are we entering into the agreement with Novartis
Why are we entering into the agreement with Novartis Novartis: Both parties commit to manufacturing, supply and global access, aiming to logistics for global reach make candidates available to all countries in need A common sense of principles, purpose, and urgency Molecular Partners: two Novartis h
Slide 16: Key messages
Key messages ▪ Molecular Partners used its pioneering DARPin® expertise to rapidly deliver two anti-COVID candidates with the potential to change the course of the pandemic ▪ Novartis has the manufacturing, supply and logistics expertise and capabilities to make DARPin candidates available to the wo
Slide 17: Commercial Framework
Commercial Framework ▪ Near term milestones total CHF 210M – F 0M ‘upfront’, including subscription of F 0M worth of MOLN ordinary shares at a price of CHF 23/share – Receipt of CHF 150M milestone upon commercial exercise (potentially achievable in before YE 2021) ▪ 22% royalties in commercial marke
Slide 18: Key Barriers overcome
Key Barriers overcome Delivering a unique therapeutic approach Creating the first multi-specific anti-viral biologic drug Building collaborations with clarity Uniting a passionate internal team with purpose-driven external experts v ’ Bringing a drug to human studies in less than 9 months 18
Slide 19: Molecular Partners AG
Molecular Partners AG Wagistrasse 14 8952 Zürich-Schlieren Switzerland www.molecularpartners.com T +41 44 755 77 00 19
Molecular Partners — FuW Forum (Covid) (October 2020) on 6ix